Back to search

Netherlands· NL-47a9cbc4c063

Brineura 150 mg oplossing voor infusie

A cerliponase alfa product containing cerliponase alfa, registered in Netherlands by BioMarin International Limited. The same ATC class is registered in 10 of our 19 countries.

ATC A16AB17

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedBrineura 150 mg oplossing voor infusieATCA16AB17REGISTER NO.NL-47a9cbc4c063PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Cerliponase alfa is registered in 10 of 19 countries.

Countries holding a registration under ATC A16AB17 (cerliponase alfa), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose

Cerliponase alfa · ATC A16AB17

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Netherlands
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
CERLIPONASE ALFA
Manufacturer
BioMarin International Limited
Country
Netherlands (NL)
ATC code
A16AB17
ATC class
Cerliponase alfa
Defined daily dose
21 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/17/1192

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Cerliponase alfa in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cerliponase alfa products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Brineura
  • Liechtenstein · Brineura
  • Norway · Brineura

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0ae6f339-3dfc-4405-ab1e-6948979dc62f
GET /v1/drugs/0ae6f339-3dfc-4405-ab1e-6948979dc62f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor infusie",
  "route": "Intracerebraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/brineura-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Cerliponase alfa",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp119521",
  "excipients": [
    "CALCIUMCHLORIDE 2-WATER (E 509)",
    "CALCIUMCHLORIDE 2-WATER (E 509)",
    "DINATRIUMWATERSTOFFOSFAAT 7-WATER (E 339)",
    "DINATRIUMWATERSTOFFOSFAAT 7-WATER (E 339)",
    "KALIUMCHLORIDE (E 508)",
    "KALIUMCHLORIDE (E 508)",
    "MAGNESIUMCHLORIDE 6-WATER (E 511)",
    "MAGNESIUMCHLORIDE 6-WATER (E 511)",
    "NATRIUMCHLORIDE",
    "NATRIUMCHLORIDE",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "WATER VOOR INJECTIE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "CERLIPONASE ALFA"
  ],
  "leaflet_url": null,
  "authorised_at": "2017/05/30",
  "procedure_number": "EMEA/H/C/004065",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/17/1192",
  "additional_monitoring": "Y"
}

See everything about cerliponase alfa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.